Companies /Healthcare
Tempus AI, Inc. Class A Common Stock
NASDAQ: TEM Health Information Services
$63.88
▲ $0.45 (+0.70%) today
Markets open · 2:45pm ET

Tempus AI (TEM) Q3 2026 Earnings

Reported Nov 2, 2026, 7:00am ET · SEC source
$0.07
Beat +191.50%
EPS · est. $-0.08 Adjusted

GAAP net loss per share of $(0.08) included $50.8 million of stock-based compensation expense and related employer payroll taxes and $42.8 million in unrealized gains on marketable securities; non-GAAP figure excludes fair value changes of $(41,490) thousand, amortization of intangibles of $16,735 thousand and acquisition-related expenses of $3,728 thousand

$411.5M
Beat +0.55%
Revenue · est. $409.3M
7 quarters
Consecutive EPS beats

How Did TEM Stock React to Q3 2026 Earnings?

+8.67%
Day of report
−0.87%
Next session
+7.59%
One week

Did TEM Beat Earnings? Q3 2026 Results

Yes. Tempus AI reported Q3 2026 earnings of $0.07 a share on Nov 2, 2026, beating the $-0.08 consensus estimate by 191.5%. Revenue was $411.5M against a $409.3M estimate.

Tempus AI delivered a decisive beat in the third quarter of 2026, posting adjusted earnings of $0.07 per share against a consensus estimate of negative $0.08, a 191.50% positive surprise that extended the company's streak of beating consensus EPS estimates to six consecutive quarters. Revenue of $411.54 million climbed 23.1% year over year and edged past the $409.30 million consensus by 0.55%, driven by strength across both reporting segments. Data and Applications revenue surged 33% to $108.07 million, with widening segment gross margin of 71.5%, while the larger Diagnostics segment contributed $303.47 million, up 20%, aided by a 300% volume increase in Minimal Residual Disease testing. Adjusted EBITDA of $25.57 million compared to just $1.48 million a year ago, underscoring the company's improving operating leverage. Recent data licensing momentum, including new multi-year collaborations with BMS, Merck, and Moderna, pushed year-to-date bookings above $550 million. Management raised full-year 2026 revenue guidance to approximately $1.60 billion, representing about 25% annual growth, while reiterating Adjusted EBITDA of roughly $65 million.

Key Takeaways
  • Oncology volume growth accelerated to 32%
  • MRD volume of ~12,000 tests, up 300%
  • Data & Applications revenue up 33%, with Insights up 29%
  • Hereditary revenue growth of only 3% offset Diagnostics growth
  • Gross margin expanded to 64.8% from 62.8%, led by Data and Applications
  • $42.8 million unrealized gains on marketable securities lifted GAAP results
  • Lower interest expense of $6.7 million vs $15.4 million a year ago

“Q3 was another record quarter, as we delivered $411.5 million of revenue, led by accelerating unit growth of 32% in our oncology business and increasing momentum of 33% revenue growth in Data & Applications.”

Tempus AI CEO, on the earnings call

What Is Tempus AI's Outlook?

Tempus raised its full-year 2026 revenue guidance to $1.60 to $1.605 billion, representing about 25% annual growth. It continues to expect 2026 Adjusted EBITDA of about $65 million. The company does not provide guidance for GAAP net loss.

TEM YoY Financials

Q3 2026 vs Q3 2025 · SEC filings Q3 2025 Q3 2026
$0$200.0M$400.0M$334.2M$411.5MRevenue$205.9M$266.7MGross Profit$-54,084,078$-56,864,000Operating Income$-8,185,526$-14,851,000Net Income
$0$200.0M$400.0MRevenueGross ProfitOperating IncomeNet Income
TEM income statement, Q3 2026 versus Q3 2025
Metric Q3 2026 Q3 2025 Year over year
Revenue $411.5M $334.2M +23.1%
Gross Profit $266.7M $205.9M +29.5%
Operating Income −$56.9M −$54.1M +5.1%
Net Income −$14.9M −$8.2M +81.4%

TEM Revenue by Segment

Diagnostics$303.5M+20.0%
Genomics
Oncology Testing (Tempus genomics)
Oncology Testing (Tempus Genomics)
Oncology Testing
Data and Applications$108.1M+33.0%
Hereditary Testing (Ambry Genetics)
Data and Services

Figures from SEC filings and company reports. Not investment advice.